pulseMD teams with Palm for physician-based ordering
pulseMD teams with Palm for physician-based orderingMedical transaction provider pulseMD is working with Palm, Pumatech, and OmniSky to deliver mobile productivity solutions for physicians. The pulseMD clinical order management service consists
pulseMD teams with Palm for physician-based ordering
Medical transaction provider pulseMD is working with Palm, Pumatech, and OmniSky to deliver mobile productivity solutions for physicians. The pulseMD clinical order management service consists of a mobile, point-to-point computing platform that enables physicians to prescribe medications, capture patient charges, and transfer the charge codes directly into practice management systems.
Using the Palm-powered platform, pulseMD has developed a healthcare application that will potentially enable thousands of physicians to automate manual processes that cost the healthcare industry billions of dollars each year, said Gabriel Acosta-Lopez, senior director of platform alliances and partner services at Palm.
- Search Again
- Return To HNN Homepage
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
